These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A novel camptothecin analog with enhanced antitumor activity.
    Author: Yount G, Yang Y, Wong B, Wang HJ, Yang LX.
    Journal: Anticancer Res; 2007; 27(5A):3173-8. PubMed ID: 17970058.
    Abstract:
    BACKGROUND: The use of camptothecin (CPT) derivatives is limited by severe toxicity associated with the instability of their chemical structure. We have developed a stable CPT derivative (CPT417) and have investigated its biological activity in comparison to the currently used CPT analogs. MATERIALS AND METHODS: The anticancer effects of CPT417 were assessed in vitro, with glioblastoma and colon cancer cell lines, and in vivo with mice bearing mammary adenocarcinoma tumors implanted subcutaneously in the flank. Cytotoxicity was assessed using vital dye exclusion, timelapse microscopy and colony formation. RESULTS: CPT417 and topotecan inhibited glioblastoma cell growth at comparable levels and both compounds inhibited clonogenicity of colon cancer cells more effectively than irinotecan. CPT417 showed a much greater inhibition of mammary tumor growth compared to topotecan, both by intraperitoneal and oral administration. CONCLUSION: CPT417 shows dramatically reduced toxicity and an enhanced antitumor activity compared to topotecan.
    [Abstract] [Full Text] [Related] [New Search]